Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
(NasdaqGM:NRIX), SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of John Northcott as chief commercial officer (CCO). Mr. Northcott has over 20 years of commercial experience, including […]